Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...

A panelist discusses how their institution prioritizes cost savings and reliable supply chain considerations when selecting biosimilars for formulary inclusion, while also weighing switching study ...

Rheumatology is a subspecialty of internal medicine focusing on the diagnosis, treatment and medical management of patients with rheumatic diseases that affect the musculoskeletal system. The ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations. Avtozma, ...

Insights regarding biosimilars in the rheumatology sector come from Samsung Bioepis’ First Quarter (Q1) 2025 Biosimilar Market Report. 6 The report highlights that the adalimumab biosimilar market ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

A few examples of biologic drugs that may be used to treat enthesitis are: Various biosimilar compounds are available for the above “branded” biologic agents. Biosimilars may be prescribed by ...

However, did you know a lot of the bots you have been using are actually examples of artificial intelligence? The bot has been designed to mimic human-like responses and perform a variety of tasks.

P.C., a seven-office rheumatology practice in Maryland; Washington, DC; and Virginia. Many other biosimilars for rheumatologic medications are launching in the next 2 years, “and we’re very ...

Initial fasting plasma glucose levels outside of 80 to 94mg/dL linked to increased risk for diabetes. HealthDay News — Fasting plasma glucose (FPG), age, body mass index (BMI), and male sex are ...

The FDA has approved a third biosimilar for tocilizumab ... Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable divergence ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...